Assignee
PROCELLA THERAPEUTICS AB
SE·8 granted patents·2 pending applications·23 citations·filing 2015–2023
Top patents by PatentIndex Score
10 records- 0188US10596200B2Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2015·Granted Mar 24, 2020·4 cites·12 claims
- 0287US11186820B2Use of Neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2018·Granted Nov 30, 2021·3 cites·16 claims
- 0386US10612094B2Genetic markers for engraftment of human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2017·Granted Apr 7, 2020·5 cites·38 claims
- 0481US11401508B2Methods for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2019·Granted Aug 2, 2022·2 cites·12 claims
- 0581US10597637B2Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2015·Granted Mar 24, 2020·4 cites·5 claims
- 0680US10508263B2Methods for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2017·Granted Dec 17, 2019·4 cites·31 claims
- 0778US11725244B2Genetic markers for engraftment of human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2020·Granted Aug 15, 2023·1 cites·21 claims
- 0874US12404488B2Use of neuropilin-1 (NRP1) as a cell surface marker for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2021·Granted Sep 2, 2025·0 cites·6 claims
- 0974US2023383345A1Genetic markers for engraftment of human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2023·Application pending·0 cites
- 1061US2020268803A1Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cellsPROCELLA THERAPEUTICS AB·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →